• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

Olaparib has similar safety in germline mutated pancreatic cancer across all age groups

August 6, 2020
-
News
-
Posted by seoaccount medivisual
Olaparib-admac

At ESMO World Congress on Gastrointestinal Cancer 2020 Virtual (1-4 July), the findings of additional analysis of the POLO trial in Chicago depicted that in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer, the efficacy and safety of maintenance olaparib is consistent irrespective of age. Furthermore, from the maintenance treatment, a long-term PFS (progression-free survival) benefit and durable tumor response can be derived in patients older than 65 years.

In patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer whose disease had not advanced during first-line platinum-based chemotherapy, treatment with maintenance olaparib yielded a statistically significant and clinically meaningful improvement in PFS when compared to placebo in the phase III POLO study.

While a subgroup analysis showed that the treatment had a consistent impact across prespecified groups, the HR (hazard ratio) was illustrated to be 1.02 in patients aged ≥65 years according to 2019 publication by Golan et al. in “The New England Journal of Medicine”.

Additional analysis by age group was carried out to better investigate the safety and efficacy of olaparib. After at least 16 weeks of treatment with first-line platinum-based chemotherapy, individuals without progression were randomly assigned to either maintenance olaparib group (n=92) or placebo group (n=62) until unacceptable toxicity or disease progression.

Utilizing modified RECIST (Response evaluation criteria in solid tumors) v1.1, the PFS and response were determined. The number of patients aged ≥65 in both groups is shown in the following table:

Olaparib group Placebo group
Number of patients aged ≥65 28/92 (30%) 13/62 (21%)

Median time from diagnosis to randomization was shorter in patients ≥65 years compared to those <65 years. The percentage of older patients having ECOG (Eastern Cooperative Oncology Group) performance status 0 is depicted in the following table:

Patients ≥65 years Patients < 65 years
Olaparib group Placebo group Olaparib group Placebo group
% of older patients having ECOG  performance status 0 64 % 46 % 73 % 65 %
Median time from diagnosis to randomization 6.1 months 6.8 months 7.3 months 7.1 months

Between age groups, no considerable difference in median baseline EORTC QLQ-C30 (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire) physical functioning score was witnessed (scale 0-100, a higher score represents higher functioning) as shown below:

Patients ≥ 65 years Patients < 65 years
Olaparib group Placebo group Olaparib group Placebo group
Median baseline EORTC QLQ-C30 physical functioning score 87 80 87 87

By 15 January 2019, 11% (3/28) patients older than 65 years, and 11% (7/64) patients less than 65 years had received olaparib for at least two years. At one and two years, the percentage of patients remaining progression-free is depicted in the table. However, between-group comparisons may be impacted by small subgroups. The number of patients attaining PR (partial response) (n=3) or CR (complete response (n=1) to maintenance olaparib and placebo arm is shown below:

Patients ≥ 65 years Patients < 65 years
Olaparib group Placebo group Olaparib group Placebo group
% of patients remaining progression-free
At one year 21 % 41 % 39 % 9 %
At two years 21 % 0 % 23 % 9 %
Number of patients attaining a partial or complete response
4/28 (14%) 3/13 (23%) 14/64 (22%) 3/49 (6%)

In patients more than 65 years, three partial responses and one complete response were noted in the olaparib group. In patients more than 65 years, one complete response was noted in the olaparib group. All partial responses were noted in the placebo group.

Among older responders, the duration of first-line chemotherapy was between 3.7-5.6 months. Baseline characteristics displayed consistency with younger responders. The complete responders who were older than 65 years had metastatic lung disease and had received 5.6 months of first-line chemotherapy.
At the data cut-off, response duration among older participants was 10.2-32.2 months, and three of four responses were ongoing.

Percentage of patients experiencing a grade ≥3 adverse event is shown in the following table:

Patients ≥ 65 years Patients < 65 years
Olaparib group Placebo group Olaparib group Placebo group
% of patients experienced a grade ≥3 adverse event 43 % 33 % 38 % 21 %

Between the two age groups, adverse-event and health-related quality of life profiles were consistent. In the overall population, no baseline characteristics were predictive of olaparib efficacy in participants older than 65 years. Thus, the efficacy of olaparib as maintenance therapy was not impacted by age of patients. However, the subgroups examined were small.

Source ESMO
Link: https://www.esmo.org/oncology-news/maintenance-olaparib-in-elderly-patients-with-a-germline-brca-mutation-and-metastatic-pancreatic-cancer [Last accessed on: 22 July, 2020]
Original title of the article Maintenance olaparib in elderly patients with a germline BRCA mutation and metastatic pancreatic cancer

 

← PREVIOUS POST
Lurbinectedin receives FDA-approval to treat metastatic SCLC
NEXT POST →
Quercetin: Cancer-fighting food ingredient

Related News

Other posts that you should not miss.
Pembrolizumab-for-colorectal-cancer-treatment-admac

FDA granted approval to Pembrolizumab for Colorectal Cancer Treatment

September 8, 2020
-
News

For the first-line treatment of patients with unresectable or metastatic MSI-H (microsatellite instability-high) or dMMR (mismatch repair deficient) colorectal cancer, the United States Food and Drug Administration (US …

Read More →
Posted by seoaccount medivisual
1 MIN READ
olive-oil-for-cancer-admac

Olive oil: A potent natural oil to prevent Colorectal Cancer

September 24, 2020
-
News

Colorectal cancer (also known as colorectal adenocarcinoma) is the fourth cause of cancer-related mortality and the third most common cancer worldwide. The incidence of this deadly cancer is …

Read More →
Posted by seoaccount medivisual
5 MIN READ
Can-helicobacter-pylori-cause-gastric-cancer-admac

Association between HelicoBacter Pylori and Gastric Cancer

December 15, 2020
-
News

Helicobacter pylori is a gastric pathogen. Infection with H. pylori causes chronic inflammation and considerably raises the risk of gastric and duodenal ulcer disease and gastric cancer. Infection …

Read More →
Posted by seoaccount medivisual
5 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
Olaparib has similar safety in germline mutated pancreatic cancer across all age groups - ADMAC Life Science